Eprosartan - Wiki slovník

Eprosartan
Clinical data
Trade names	Teveten
AHFS/Drugs.com	Monograph
MedlinePlus	a601237
License data	US DailyMed: Eprosartan;
Pregnancy; category	AU: D; ;
Routes of; administration	By mouth
ATC code	C09CA02 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); US: ℞-only;
Pharmacokinetic data
Bioavailability	15% (Eprosartan mesylate)
Metabolism	not metabolized
Elimination half-life	5 to 9 hours
Excretion	Kidney 10%, bile duct 90%
Identifiers
	IUPAC name 4-({2-Butyl-5--1H-imidazol-1-yl}methyl)benzoic acid;
CAS Number	133040-01-4 ;
PubChem CID	5281037;
IUPHAR/BPS	588;
DrugBank	DB00876 ;
ChemSpider	4444504 ;
UNII	2KH13Z0S0Y;
KEGG	D04040 ; as mesylate: D02082 ;
ChEBI	CHEBI:4814 ;
ChEMBL	ChEMBL813 ;
CompTox Dashboard (EPA)	DTXSID0022989 ;
Chemical and physical data
Formula	C23H24N2O4S
Molar mass	424.52 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(O)\C(=C\c1cnc(n1Cc2ccc(C(=O)O)cc2)CCCC)Cc3sccc3;
	InChI InChI=1S/C23H24N2O4S/c1-2-3-6-21-24-14-19(12-18(23(28)29)13-20-5-4-11-30-20)25(21)15-16-7-9-17(10-8-16)22(26)27/h4-5,7-12,14H,2-3,6,13,15H2,1H3,(H,26,27)(H,28,29)/b18-12+ ; Key:OROAFUQRIXKEMV-LDADJPATSA-N ;
	(verify)

Eprosartan, sold under the brand name Teveten among others, is an angiotensin II receptor antagonist used for the treatment of high blood pressure.^[1]

Eprosartan is sometimes paired with hydrochlorothiazide.^[2]

As with other angiotensin II receptor antagonists, eprosartan is generally better tolerated than enalapril (an ACE inhibitor), especially among the elderly.^[3]

History

The compound came into the Abbott Laboratories cardiovascular pipeline with its acquisition of Kos Pharmaceuticals in 2006, which had licensed it, along with "a range of hypertensive treatments", from the Biovail Corporation.^[4]

References

^ "Eprosartan mesylate- eprosartan mesylate tablet, film coated". DailyMed. Retrieved 7 June 2023.
^ "Teveten HCT- eprosartan mesylate and hydrochlorothiazide tablet". DailyMed. 3 January 2012. Retrieved 7 June 2023.
^ Ruilope L, Jäger B, Prichard B (2001). "Eprosartan versus enalapril in elderly patients with hypertension: a double-blind, randomized trial". Blood Press. 10 (4): 223–9. doi:10.1080/08037050152669747. PMID 11800061. S2CID 13063704.
^ Anon., 2006, Abbott Laboratories: Kos Pharmaceuticals a wise buy, Datamonitor ResearchStore (online), November 8, 2006, see , accessed 29 January 2015.

Zdroj:https://en.wikipedia.org?pojem=Eprosartan
>Text je dostupný pod licencí Creative Commons Uveďte autora – Zachovejte licenci, případně za dalších podmínek. Podrobnosti naleznete na stránce Podmínky užití.

[1] "Eprosartan mesylate- eprosartan mesylate tablet, film coated". DailyMed. Retrieved 7 June 2023.

[2] "Teveten HCT- eprosartan mesylate and hydrochlorothiazide tablet". DailyMed. 3 January 2012. Retrieved 7 June 2023.

[3] Ruilope L, Jäger B, Prichard B (2001). "Eprosartan versus enalapril in elderly patients with hypertension: a double-blind, randomized trial". Blood Press. 10 (4): 223–9. doi:10.1080/08037050152669747. PMID 11800061. S2CID 13063704.

[4] Anon., 2006, Abbott Laboratories: Kos Pharmaceuticals a wise buy, Datamonitor ResearchStore (online), November 8, 2006, see , accessed 29 January 2015.

[1]

[2]

[3]

[4]

v t e Antihypertensive drugs acting on the renin–angiotensin system (C09)
ACE inhibitors ("-pril")	Sulfhydryl-containing: Captopril Rentiapril Zofenopril Dicarboxylate-containing: Enalapril^# Benazepril Cilazapril Delapril Imidapril Lisinopril (+amlodipine, +HCT) Moexipril Perindopril (+indapamide) Quinapril (+HCT) Ramipril Spirapril Temocapril Trandolapril Phosphonate-containing: Ceronapril Fosinopril (+HCT) Other/ungrouped: Alacepril
AIIRAs ("-sartan")	Azilsartan Candesartan Eprosartan Fimasartan Irbesartan (+HCT) Losartan (+HCT) Olmesartan (+amlodipine, +amlodipine and HCT, +HCT) Tasosartan^§ Telmisartan (+amlodipine, +HCT) Valsartan (+amlodipine, +amlodipine and HCT, +HCT, +nebivolol)
Renin inhibitors ("-kiren")	Aliskiren (+amlodipine, +HCT, +amlodipine and HCT) Remikiren^§
Dual ACE/NEP inhibitors	Gemopatrilat Ilepatril Omapatrilat Sampatrilat
Neprilysin inhibitors	Sacubitril (+valsartan)
^#WHO-EM ^‡Withdrawn from market Clinical trials: ^†Phase III ^§Never to phase III